Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development.
Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies.
Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.
Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies.
Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.
Location: United Kingdom
Employees: 11-50
Total raised: $114.59M
Founded date: 2019
Founders name: Uri Laserson
Founders Related Locations: United States, New York, New York
Investors 7
| Date | Name | Website |
| - | DCVC | dcvc.com/ |
| - | Camford Ca... | camford.co... |
| - | RA Capital... | racap.com |
| 22.04.2021 | Lightstone... | lightstone... |
| - | DHVC | dh.vc |
| - | SV Health ... | svhealthin... |
| 01.10.2025 | Ono Ventur... | onoventure... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 09.09.2025 | - | $32M | Eli Lilly ... |
| 15.04.2021 | Series A | $82.59M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Uri | Laserson | Scientific... | linkedin.c... | - | - |
Mentions in press and media 15
| Date | Title | Description |
| 03.10.2025 | Ono Venture Investment invests in Alchemab. (Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension) | - |
| 09.09.2025 | Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension | Cambridge, UK, 9 September 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company which identifies and develops naturally occurring therapeutic antibodies from resilient individuals, today announced initiation of a Phase 1 fir... |
| 09.09.2025 | Alchemab Therapeutics Raises Series A Extension Financing | Alchemab Therapeutics, a London, UK-based biopharmaceutical company which identifies and develops naturally occurring therapeutic antibodies from resilient individuals, raised an undisclosed amount in Series A extension funding. Backers inc... |
| 08.03.2024 | On International Women's Day SV Venture Partner Ruth McKernan reflects on some achievements of SV biotech portfolio companies | On International Women’s Day it is extremely pleasing to note the vast majority of SV Health Investor’s biotech portfolio companies with women in their C-suite, many being led by female CEOs. It is one of the many reasons I was drawn to wor... |
| 26.05.2022 | Alchemab appoints Young T. Kwon as Chief Executive Officer | Waltham, Massachusetts and Cambridge, UK May 26, 2022 – Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification ... |
| 22.06.2021 | Alchemab Therapeutics Appoints Douglas A. Treco, PhD as Chief Executive Officer | Industry Veteran Brings Experience and Proven Track Record of Success |
| 05.05.2021 | Alchemab to collaborate with AstraZeneca to use Alchemab’s drug discovery platform for prostate cancer study | Alchemab to collaborate with AstraZeneca to use Alchemab’s drug discovery platform for prostate cancer study 05-05-2021 Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat diseases by harnessing the pow... |
| 15.04.2021 | Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics | April 15, 2021 04:00 AM Eastern Daylight Time |
| 15.04.2021 | Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics | Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A f... |
| 15.04.2021 | Alchemab raises £60 million in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics | Alchemab raises £60 million in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics 15-04-2021 Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-trea... |
Show more